Literature DB >> 29113178

Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: Analysis of 89 cases.

Jing Liu1, Yaming Wang2, Yuantao Liu3, Zhe Liu4, Qu Cui1, Nan Ji5, Shengjun Sun6, Bingxu Wang7, Yajie Wang8, Xuefei Sun1, Yuanbo Liu1.   

Abstract

The majority of primary central nervous system lymphomas (PCNSLs) are diffuse large B cell lymphoma, characterized by poor prognosis. In the present study, the expression of cluster of differentiation (CD)10, B cell lymphoma (BCL)-6, multiple myeloma-1 (MUM-1), BCL-2, CD138 and Ki-67 was analyzed by immunohistochemistry in 89 Chinese PCNSL cases, and the potential prognostic significance was evaluated. CD10, BCL-6, MUM-1, BCL-2 and CD138 were positive in 16.9 (15/89), 51.7 (46/89), 92.1 (82/89), 73.3 (63/86) and 0% (0/65) of all cases, respectively. According to the Hans algorithm, 71 patients (79.8%) were classified into the non-germinal center B cell-like (non-GCB) group, indicating a post-germinal center origin of PCNSL. The median follow-up time of 73 patients was 13 months [95% confidence interval (CI), 10.93-15.08]. The median overall survival (OS) time was 45.3 months (95% CI, 25.01-65.59) and the median progression-free survival (PFS) time was 30.0 months (95% CI, 13.43-46.57). Age (>60 years) was associated with a shorter OS time (P=0.009). Ki-67 (cutoff point 90%) was associated with shorter OS (P=0.037) and shorter PFS (P=0.039) times. No other immunohistochemical markers were associated with prognosis. On multivariate analysis, age (>60 years) was associated with shorter OS time (P=0.038), but immunophenotype and expression status of Ki-67, CD10, BCL-6 and BCL-2 did not predict prognosis. In conclusion, high Ki-67 expression may predict poor prognosis in PCNSL. The present study was limited by its sample size and short follow-up time. This requires more evidence to further clinical study.

Entities:  

Keywords:  Ki-67; diffuse large B cell lymphoma; germinal center B cell-like; non-germinal center B cell-like; primary central nervous system lymphoma

Year:  2017        PMID: 29113178      PMCID: PMC5656017          DOI: 10.3892/ol.2017.6893

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  45 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

3.  Clinicopathological correlates of primary central nervous system lymphoma: experience from a tertiary care center in South India.

Authors:  Bimal Patel; Geeta Chacko; Sheila Nair; Jamie Anandan; Ari G Chacko; Vedantam Rajshekhar; Mazda Turel
Journal:  Neurol India       Date:  2015 Jan-Feb       Impact factor: 2.117

4.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial.

Authors:  T P Miller; T M Grogan; S Dahlberg; C M Spier; R M Braziel; P M Banks; K Foucar; C R Kjeldsberg; N Levy; B N Nathwani
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

5.  Bcl-6 predicts improved prognosis in primary central nervous system lymphoma.

Authors:  Oren Levy; Lisa M Deangelis; Daniel A Filippa; Katherine S Panageas; Lauren E Abrey
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

6.  Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.

Authors:  Adi Broyde; Olga Boycov; Yulia Strenov; Elimelech Okon; Ofer Shpilberg; Osnat Bairey
Journal:  Am J Hematol       Date:  2009-06       Impact factor: 10.047

7.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.

Authors:  Ching-Hung Lin; Kuan-Ting Kuo; Shih-Sung Chuang; Sung-Hsin Kuo; Julia Hueimei Chang; Kung-Chao Chang; Hui-Chen Hsu; Hwei-Fang Tien; Ann-Lii Cheng
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

9.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

10.  BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.

Authors:  Kristina M Braaten; Rebecca A Betensky; Laurence de Leval; Yoshifumi Okada; Fred H Hochberg; David N Louis; Nancy L Harris; Tracy T Batchelor
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

View more
  12 in total

1.  BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Keishi Makino; Hideo Nakamura; Naoki Shinojima; Jun-Ichiro Kuroda; Shigetoshi Yano; Yoshiki Mikami; Akitake Mukasa
Journal:  J Neurooncol       Date:  2018-07-02       Impact factor: 4.130

Review 2.  Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?

Authors:  K Grace Ho; Christian Grommes
Journal:  Curr Opin Neurol       Date:  2019-12       Impact factor: 5.710

Review 3.  Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.

Authors:  Kensuke Tateishi; Yohei Miyake; Taishi Nakamura; Tetsuya Yamamoto
Journal:  Brain Tumor Pathol       Date:  2021-07-13       Impact factor: 3.298

4.  Undifferentiated sinonasal malignant melanoma: A case report.

Authors:  Jun Du; Liang-Liang Huang; Ao Xu; An-Li Zhang; Xue Kong; Min Ding; Wen Hu; Zhen-Li Guo; Wen Zhong; Si-Bai Sun; Heng Li; Jie Chen; Qian Shen; Lu-Lu Xu; Hai-Bo Wu
Journal:  Oncol Lett       Date:  2018-05-08       Impact factor: 2.967

5.  Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome.

Authors:  Insun Chong; Quinn Ostrom; Bilal Khan; Dima Dandachi; Naveen Garg; Aikaterini Kotrotsou; Rivka Colen; Fanny Morón
Journal:  Cancers (Basel)       Date:  2019-10-08       Impact factor: 6.639

6.  Primary Central Nervous System Lymphoma in an Immunocompetent Patient Presenting as Multiple Cerebellar Lesions: A Case Report and Review of Literature.

Authors:  Gliceida M Galarza Fortuna; Kathrin Dvir; Christopher Febres-Aldana; Michael Schwartz; Ana Maria Medina
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

Review 7.  Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.

Authors:  Marietya I S Lauw; Calixto-Hope G Lucas; Robert S Ohgami; Kwun Wah Wen
Journal:  Diagnostics (Basel)       Date:  2020-12-11

8.  Analysis of Cellular Heterogeneity in Immune Microenvironment of Primary Central Nervous System Lymphoma by Single-Cell Sequencing.

Authors:  Boyuan Wei; Zhe Liu; Yue Fan; Shuwei Wang; Chao Dong; Wei Rao; Fan Yang; Gang Cheng; Jianning Zhang
Journal:  Front Oncol       Date:  2021-10-04       Impact factor: 6.244

Review 9.  Update on Novel Therapeutics for Primary CNS Lymphoma.

Authors:  Lauren R Schaff; Christian Grommes
Journal:  Cancers (Basel)       Date:  2021-10-26       Impact factor: 6.639

10.  Up-regulation of microRNA-497 inhibits the proliferation, migration and invasion but increases the apoptosis of multiple myeloma cells through the MAPK/ERK signaling pathway by targeting Raf-1.

Authors:  Cheng-Yu Ye; Cui-Ping Zheng; Wei-Wei Ying; Shan-Shan Weng
Journal:  Cell Cycle       Date:  2018-12-11       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.